UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 膵外分泌癌の臨床症状、診断、および病期分類clinical manifestations diagnosis and staging of exocrine pancreatic cancer [show details]
…level ≥130 units/mL versus <130 units/mL were 26 and 11 percent, respectively. Among patients with tumors in the body/tail of the pancreas, more than one-third of those who had a CA 19-9 level ≥130 units/mL …
2. 上皮性卵巣癌、卵管癌、または原発性腹膜癌患者の付属器腫瘤の評価のための血清バイオマーカーserum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary fallopian tube or peritoneum [show details]
… apolipoprotein A1) . OVA1 is performed exclusively through Quest Diagnostics, which is available in over 130 countries worldwide. The proprietary OvaCalc software combines the values for each assay and uses the… Cancer antigen 19-9 (CA 19-9) is a mucin protein that may be elevated in EOC but is used sparingly in ovarian cancer management . More commonly, CA 19-9 is used to monitor…
3. 胆管癌の臨床症状および診断clinical manifestations and diagnosis of cholangiocarcinoma [show details]
…Serum levels of CA 19-9 are widely used for detecting cholangiocarcinoma in patients with PSC . Elevated levels of CA 19-9 prior to treatment are associated with a poorer prognosis , and CA 19-9 concentrations …
4. 進行性膵外分泌癌に対する二次全身療法second line systemic therapy for advanced exocrine pancreatic cancer [show details]
… 41 patients who failed one prior chemotherapy regimen received oxaliplatin (130 mg/m² every three weeks,… Serum levels of the tumor marker carbohydrate antigen 19-9 (CA 19-9; also called cancer antigen 19-9),…
5. 虫垂上皮性腫瘍epithelial tumors of the appendix [show details]
… chemotherapy backbone was addressed in an analysis of 130 patients with unresectable appendiceal epithelial neoplasms;…associated with gastrointestinal tract tumors, particularly carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and cancer antigen 125 (CA-125). For example, in the case of colorectal cancer, CEA …

Related Links

130. バイセクト糖鎖の選択的発現機構と作動原理の解明木塚康彦

130. バイセクト糖鎖の選択的発現機構と作動原理の解明木塚康彦岐阜大学研究推進社会連携機構生命の鎖統合研究センター Key words：バイセクト糖鎖，糖転移酵素，糖鎖生物学，神経系，ⅢGnT- 緒言哺乳動物の半数以上の

腫瘍マーカーの見方

10 糖鎖抗原はその抗原決定基の構造から % と仮定して陽性的中率を計算した。有病率の低い一般診療所で腫瘍マーカーを用いると，陽性的中率はわずか約 4 型糖鎖： % である。すなわち 96 癌，% に誤警告をすることになる。誤 ...

主な検査項目基準値一覧 2020年4月1日更新基準範囲単位 ...

74 シアル化糖鎖抗原KL-6 KL-6 105 401 U/ml 75 Duke法 1M00S 5M00S M S 76 プロトロンビン-％ PT-％ 90 130 ％ 77 プロトロンビン-秒 PT-秒 10.4 12.3 秒 78 プロトロンビン-INR PT-INR 0.87 1.03 79 活性化部分トロンボプラスチン 80 ...